SCHEMBL29624176

SCHEMBL29624176

Fc1ccccc1CCNC(=S)Nc1ccc(Br)cn1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.70
LTC4S Q16873 2/20 0.61
RAB9A P51151 8/20 0.50
SMN1; SMN2 Q16637 5/20 0.50
KMT2A Q03164 4/20 0.50
LMNA P02545 3/20 0.50
PKM P14618 2/20 0.50
MAPT P10636 5/20 0.46
POLB P06746 2/20 0.46
MEN1 O00255 3/20 0.46
ALOX12 P18054 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
GAA P10253 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
NPC1 O15118 5/20 0.43
HIF1A Q16665 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5390696 1.00 ALDH1A1 (0.70) ALDH1A1LTC4SRAB9ASMN1; SMN2KMT2A
SCHEMBL6351301 0.93 ALDH1A1 (0.61) ALDH1A1LTC4SRAB9ASMN1; SMN2KMT2A
SCHEMBL6905477 0.86 ALDH1A1 (0.67) ALDH1A1LTC4SRAB9ASMN1; SMN2KMT2A
SCHEMBL6965655 0.86 ALDH1A1 (0.71) ALDH1A1LTC4SRAB9ASMN1; SMN2KMT2A
SCHEMBL5888457 0.85 ALDH1A1 (0.70) ALDH1A1LTC4SRAB9ASMN1; SMN2KMT2A
SCHEMBL6270813 0.82 ALDH1A1 (0.65) ALDH1A1LTC4SRAB9ASMN1; SMN2KMT2A
SCHEMBL14439883 0.82 ALDH1A1 (0.62) ALDH1A1LTC4SRAB9ASMN1; SMN2KMT2A
SCHEMBL29355043 0.82 ALDH1A1 (1.00) ALDH1A1LTC4SRAB9ASMN1; SMN2KMT2A
SCHEMBL7624466 0.82 ALDH1A1 (1.00) ALDH1A1LTC4SRAB9ASMN1; SMN2KMT2A
SCHEMBL6964103 0.82 ALDH1A1 (0.67) ALDH1A1RAB9AKMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250000821-A1 METHODS OF USING DIPIVEFRIN Insignis Therapeutics, Inc. 2025-01-02 US disclosed
CN-111565716-B Method of using dipivefrin 因斯格尼斯疗法有限公司 2023-06-09 CN disclosed
US-20220193010-A1 METHODS OF USING DIPIVEFRIN INSIGNIS THERAPEUTICS INC (US) 2022-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250000821-A1 METHODS OF USING DIPIVEFRIN QDPR, DNPEP, DPEP1 ALDH1A1 1423/4885LTC4S 1053/4885RAB9A 3101/4885
US-20220193010-A1 METHODS OF USING DIPIVEFRIN QDPR, DNPEP, DPEP1 ALDH1A1 1423/4885LTC4S 1053/4885RAB9A 3101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.